Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712590 | 1.00 | NR1H4 (0.46) | NR1H4CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL2349507 | 0.94 | NR1H4 (0.49) | NR1H4CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL2346833 | 0.86 | TSHR (0.46) | NR1H4CYP3A4ADORA3HTTMEN1 | |
| SCHEMBL1712136 | 0.85 | ADORA3 (0.44) | NR1H4CYP3A4CYP2D6CYP2C9CNR1 | |
| SCHEMBL1712358 | 0.81 | NR1H4 (0.46) | NR1H4CYP3A4CYP2D6CYP2C9ADORA3 | |
| SCHEMBL2349518 | 0.81 | NR1H4 (0.49) | NR1H4CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL2345795 | 0.81 | NR1H4 (0.49) | NR1H4CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1712275 | 0.80 | NR1H4 (0.42) | NR1H4CYP3A4CYP2C9KCNH2CNR1 | |
| SCHEMBL1712658 | 0.80 | NR1H4 (0.52) | NR1H4CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1712075 | 0.78 | ADORA3 (0.45) | NR1H4CYP2D6CNR1CNR2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | claimed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | claimed |
| CN-102164899-A | 2, 3-substituted indazoles or 4,5,6, 7-tetrahydro-indazoles as FXR modulators against dyslipidemia and related diseases | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | claimed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | claimed |
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| CN-102164899-A | 2, 3-substituted indazoles or 4,5,6, 7-tetrahydro-indazoles as FXR modulators against dyslipidemia and related diseases | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | disclosed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, ABCB11, FXR1 | NR1H4 1/4885CYP3A4 36/4885CYP2D6 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.